Pemetrexed Plus Cisplatin Bi-Weekly, in Patients With Urothelial Cancer (Metastatic, Locally Advanced or Non-Resectable)

NCT00374868 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Urologic Neoplasms

Interventions

DRUG: pemetrexed
DRUG: cisplatin

Sponsor

Eli Lilly and Company